CO2021001528A2 - Combinación farmacéutica sinérgica de un inhibidor selectivo de la ciclooxigenasa 2 y un derivado de antraquinona - Google Patents

Combinación farmacéutica sinérgica de un inhibidor selectivo de la ciclooxigenasa 2 y un derivado de antraquinona

Info

Publication number
CO2021001528A2
CO2021001528A2 CONC2021/0001528A CO2021001528A CO2021001528A2 CO 2021001528 A2 CO2021001528 A2 CO 2021001528A2 CO 2021001528 A CO2021001528 A CO 2021001528A CO 2021001528 A2 CO2021001528 A2 CO 2021001528A2
Authority
CO
Colombia
Prior art keywords
inhibitor
pharmaceutical combination
selective cyclooxygenase
anthraquinone derivative
synergistic pharmaceutical
Prior art date
Application number
CONC2021/0001528A
Other languages
English (en)
Inventor
Armenta Patricia Del Carmen García
García José Alonso Chávez
Original Assignee
Amezcua Amezcua Federico
Amezcua Amezcua Carlos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amezcua Amezcua Federico, Amezcua Amezcua Carlos filed Critical Amezcua Amezcua Federico
Publication of CO2021001528A2 publication Critical patent/CO2021001528A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende la combinación sinérgica de un inhibidor selectivo de la COX-2, como lo es el principio activo: celecoxib y un agente derivado de antraquinona, como lo es el principio activo: diacereina, los cuales se encuentran formulados con excipientes y/o vehículos y/o aditivos farmacéuticamente aceptables en una sola unidad de dosificación para ser administrado por vía oral, parenteral, tópica, transdérmica o por dispositivos para inhalación oral, nasal, misma que está indicada para el tratamiento del dolor e inflamación en osteoartritis, artritis reumatoide y/o enfermedad articular degenerativa por diversas etiologías.
CONC2021/0001528A 2018-09-13 2021-02-10 Combinación farmacéutica sinérgica de un inhibidor selectivo de la ciclooxigenasa 2 y un derivado de antraquinona CO2021001528A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2018011142A MX2018011142A (es) 2018-09-13 2018-09-13 Combinacion farmaceutica sinergica de un inhibidor selectivo de la ciclooxigenasa 2 y un derivado de antraquinona.
PCT/MX2019/000097 WO2020055226A1 (es) 2018-09-13 2019-09-12 Combinación farmacéutica sinérgica de un inhibidor selectivo de la ciclooxigenasa 2 y un derivado de antraquinona

Publications (1)

Publication Number Publication Date
CO2021001528A2 true CO2021001528A2 (es) 2021-03-08

Family

ID=69416590

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0001528A CO2021001528A2 (es) 2018-09-13 2021-02-10 Combinación farmacéutica sinérgica de un inhibidor selectivo de la ciclooxigenasa 2 y un derivado de antraquinona

Country Status (6)

Country Link
US (1) US20210252025A1 (es)
EP (1) EP3851104A4 (es)
CA (1) CA3109212A1 (es)
CO (1) CO2021001528A2 (es)
MX (1) MX2018011142A (es)
WO (1) WO2020055226A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020061475A2 (en) * 2018-09-21 2020-03-26 The Johns Hopkins University Compositions and methods for treating metabolic disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA761627B (en) 1976-03-16 1978-01-25 C Friedmann Improvements in or relating to the treatment of arthritis
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
WO2003000246A1 (en) * 2001-06-25 2003-01-03 Arakis Ltd. The use of rhein and derivatives thereof in pain treatment
WO2004018312A1 (en) 2002-08-21 2004-03-04 Pharmacia Corporation Injectable pharmaceutical suspension in a two-chamber vial
US8574625B2 (en) 2007-05-30 2013-11-05 Wockhardt Ltd. Tablet dosage form
US20140336148A1 (en) * 2011-12-27 2014-11-13 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Combinations of diacerein and non-steroidal inflammation drugs
AR096438A1 (es) 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido con perfil de liberación bimodal, proceso
NO3057589T3 (es) 2014-05-09 2017-12-30

Also Published As

Publication number Publication date
WO2020055226A1 (es) 2020-03-19
MX2018011142A (es) 2019-10-10
EP3851104A1 (en) 2021-07-21
CA3109212A1 (en) 2020-03-19
US20210252025A1 (en) 2021-08-19
EP3851104A4 (en) 2022-06-29

Similar Documents

Publication Publication Date Title
PE20210401A1 (es) Composiciones farmaceuticas que comprenden meloxicam
CL2017002939A1 (es) Composiciones farmacéuticas tópicas
CL2019003542A1 (es) Métodos de tratamiento para la fibrosis quística.
CO6700827A2 (es) Corticosteroides para el tratamiento de dolor de articulaciones
BR112020015688A8 (pt) Formulações tópicas que compreendem tofacitinibe
AR105808A1 (es) Compuestos de amida para el tratamiento de trastornos médicos
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
CO2018004206A2 (es) Formulación farmacéutica para administración oral que comprende un compuesto de 25-hidroxi vitamina d”
BR112015019264A8 (pt) cápsulas para o tratamento de helicobacter pylori e seu uso".
BR112017016087A2 (pt) formulações para coxim articular adiposo e métodos de uso das mesmas
CO2019007409A2 (es) Derivados de la pirimidin enona tricíclica para la inhibición de rorγ y otros usos
EA200870469A1 (ru) Новые, содержащие нимесулид, фармацевтические композиции с низкой дозой, их получение и применение
CO2021001528A2 (es) Combinación farmacéutica sinérgica de un inhibidor selectivo de la ciclooxigenasa 2 y un derivado de antraquinona
ECSP099734A (es) Composición farmaceutica que comprende la combinación de un agente antiinflamatorio no esteroideo y un agente anticonvulsivante
CO2020001887A2 (es) Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático
BR112022003867A2 (pt) Conjugado anticorpo-droga (adc), composição farmacêutica e adc para seu uso ou composição para seu uso
BR112019018185A2 (pt) composição para tratar uma doença de articulação humana, e, kit.
EA201890616A1 (ru) Сульфонамидные соединения в качестве модуляторов потенциалуправляемых натриевых каналов
ECSP10010054A (es) Composiciones farmacéuticas que comprenden la combinación de un agente antiinflamatorio no esteroideo y un agente inhibidor de la xantino oxidasa útiles para el control y tratamiento de la gota, artritis gotosa y enfermedades relacionadas
CO2021000026A2 (es) Composición farmacéutica sinérgica de aceclofenaco y betametasona para el tratamiento del dolor en las formas localizadas de afecciones reumáticas
CO2021010388A2 (es) Composición farmacéutica sinérgica de aceclofenaco y betametasona para el tratamiento del dolor de afecciones reumáticas o dolor postquirúrgico
AR102295A1 (es) Compuesto derivado de pirazolina y su uso en un régimen de dosificación semanal contra inflamación y dolor derivados de enfermedad articular degenerativa en mamíferos
CL2021000627A1 (es) Composiciones farmacéuticas adecuadas para liberación articular y su uso en el tratamiento del dolor articular
CO2021006473A2 (es) Composición farmacéutica que comprende la combinación de un inhibidor selectivo de la ciclooxigenasa 2 y un carbamato derivado de la guaifenesina para el tratamiento del dolor, inflamación y contractura muscular
CL2018003707A1 (es) Regímenes de dosificación de vortioxetina para el rápido inicio del efecto antidepresivo.